Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Millennium Research and Clinical Development LLC

Neither a doctor nor a teaching hospital

Research payments

$2,716,579

222 payments

Through program year 2025, Millennium Research and Clinical Development LLC is reported as receiving $2,716,579 in research payments, across 222 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $273,551 36
2024 Research $178,777 36
2023 Research $886,950 91
2022 Research $1,135,099 45
2021 Research $242,202 14

Breakdown

Who paid Research payments · program years 2021–2025
  1. G1 Therapeutics, Inc. $1,658,617 79 payments
  2. BioNTech SE $235,021 30 payments
  3. Daiichi Sankyo Inc. $205,596 48 payments
  4. Merck Sharp & Dohme Corporation $150,332 1 payment
  5. GlaxoSmithKline, LLC. $143,118 18 payments
  6. Genentech, Inc. $122,276 22 payments
  7. Mirati Therapeutics, Inc. $66,096 9 payments
  8. Amgen Inc. $40,680 2 payments
  9. Regeneron Pharmaceuticals, Inc. $29,373 5 payments
  10. Merck Healthcare KGaA $24,610 4 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) $911,941 39 payments
  2. G1t28-207 $746,675 40 payments
  3. Ds7300-127 $205,596 48 payments
  4. A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer $150,332 1 payment
  5. A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the S $143,118 18 payments
  6. Phase III Study of Giredestrant Everolimus VS Everolimus Exemestane in Er Her2 Locally Adv Or MBC $122,276 22 payments
  7. Bnt327-06 $112,644 10 payments
  8. Bnt327-07 $90,863 16 payments
  9. A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy $66,096 9 payments
  10. A Phase 1/2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% $29,373 5 payments
What the money was spent on Research payments · program years 2021–2025
  1. Non-patient care $51,876 5 payments
  2. Patient care $14,220 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record